A post hoc analysis of the KEYNOTE-671 study presented at the World Conference on Lung Cancer in 2024 revealed that the amount of residual tumor after surgery in early-stage non–small cell lung cancer impacts event-free survival (EFS). Perioperative pembrolizumab was found to be beneficial over placebo in this context. The analysis showed that a greater degree of pathologic regression was associated with better EFS time, regardless of treatment arm. Further studies are needed to validate the use of %RVT for evaluating outcomes in this patient population. The study also compared results with CheckMate 816, highlighting the need for more effective personalized treatments and biomarkers in early-stage NSCLC.
Source link
EFS Depends on Residual Tumor in NSCLC
